Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Velcade and Dexamethasone in Newly Diagnosed Multiple Myeloma
NCT00337506Phase 2Terminated
- Sponsor
- CHU de Nantes
- Start
- Aug 2003
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in multiple myeloma (MM), sponsored by CHU de Nantes. Primary endpoints: Complete remission, Disappearance of serum and/or urine M-component and 2 more. Started Aug 2003; status: terminated.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00337506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00337506.